scleroderma Flashcards
localised scleroderma (skin&dermis)
morphea
linear morphea
en coupe de Sabre
systemic sclerosis
limited systemic sclerosis
diffuse systemic sclerosis
pathophysiology of systemic sclerosis
imbalance between local vasodilators and vaso constrictors, activated endothelium, adhesion of inflammatory cells.
platelet aggregation, fibrin deposition and intravascular thrombosis and a fibrotic reaction due to proliferation of myofibroblasts
features of vascular dysfunction
- digital ulceration & pulp atrophy
- pulmonary vessels stiffer - PAH
- renal vessels stiffer - systemic HTN
fibrosis features
- fibroblast production of collagen type I & III becomes persistent
- tissue becomes thicker
features of limited cutaneous systemic sclerosis
skin involvement is limited to hands, face, feet and forearms, BEAK nose + small mouth, starts with raynauds (CREST)
antibody in diffuse systemic sclerosis
ANAs involved:
scl-70 (highly specific) and RNA polymerase III
signs of systemic sclerosis
- small mouth, beak nose
- raynauds
- digital ulceration
- diffuse skin thickening
- interstitial lung disease
- gastrointestinal
- renal
- cardiac
investigations in systemic sclerosis
- FBC (normocytic normochromic anaemia_
- U+E
- auto antibodies (anti-centromeres in 70%, DcSSC)
- CXR (calcinassi of hands)
- barium swallowed (oesophageal motility)
signs of limited sclerosis
CREST
- calcinosis
- raynauds
- oesphageal - , acid reflux, gi general
- scleroactyl - thickening and tightening of skin, distal
- telangectasia
- scleroderma of neck and face
- pulmonary HTN
- fibrotic lung disease
- mid gut disease
- renal crisis (scl-70/RNA polymerase III)
ANAs involved
anti-centromere
symptomatic treatment of systemic sclerosis
lifestyle advice
vasodilatory drugs (preventing digital ulcers/treating PAH)
PPIs
Reno-protective drugs in systemic sclerosis
ACEi
immunosuppression
cyclophosphamide/mycophenolate/methotrexate
anti-centromere antibody (ACA)
limited cutaneous disease microvascular changes (telangectaisa) PAH GI disease raynauds